Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Unilever plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.07 (market cap $29.60B), while Unilever plc trades at $61.74 (market cap $134.06B). The key difference: Unilever plc is far larger — about 4.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Unilever plc pays a 3.65% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | UL | |
|---|---|---|
Market Cap | $29.60B | $134.06B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $74.59 |
52-Week Low | $205.48 | $55.05 |
Enterprise Value | $27.56B | $159.86B |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Unilever (UL) trades at $61.75, down 1.77% on the day, with a bearish technical signal. The stock shows strong profitability with a net income margin of 18.75% and ROE of 53.32%, but recent quarters have seen EPS misses against expectations. A major development is the planned $65 billion merger with McCormick's food business, expected to close in 2027, which could reshape growth prospects.
Outlook is mixed: robust cash flow and dividend yield near 1.75% support income investors, but execution risks on the McCormick deal and volatile earnings pose challenges. Analysts are divided, with 51% hold ratings, reflecting uncertainty amid strategic shifts. The stock appeals for its defensive staples exposure but requires monitoring of integration progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
